DSpace

RI UFBA >
Faculdade de Medicina da Bahia >
Artigos Publicados em Periódicos (Medicina) >

Please use this identifier to cite or link to this item: http://repositorio.ufba.br/ri/handle/ri/15991

Title: Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease
Other Titles: World Journal of Gastroenterology
Authors: Lyra, André Castro
Soares, Milena Botelho Pereira
Silva, Luiz Flavio Maia da
Fortes, Marcos Fraga
Silva, André Goyanna Pinheiro
Mota, Augusto César de Andrade
Oliveira, Sheilla A.
Braga, Eduardo Lorens
Carvalho, Wilson Andrade de
Genser, Bernd
Santos, Ricardo Ribeiro dos
Lyra, Luiz Guilherme Costa
Keywords: Bone marrow;Cell transplantation;Cirrhosis;Liver failure;Stem cell
Issue Date: 2007
Abstract: Aim: To evaluate the safety and feasibility of bone marrow cell (BMC) transplantation in patients with chronic liver disease on the waiting list for liver transplantation. Methods: Ten patients (eight males) with chronic liver disease were enrolled to receive infusion of autologous bone marrow-derived cells. Seven patients were classified as Child-Pugh B and three as Child-Pugh C. Baseline assessment included complete clinical and laboratory evaluation and abdominal MRI. Approximately 50 mL of bone marrow aspirate was prepared by centrifugation in a ficoll-hypaque gradient. At least of 100 millions of mononuclear-enriched BMCs were infused into the hepatic artery using the routine technique for arterial chemoembolization for liver tumors. Patients were followed up for adverse events up to 4 mo. Results: The median age of the patients was 52 years (range 24-70 years). All patients were discharged 48 h after BMC infusion. Two patients complained of mild pain at the bone marrow needle puncture site. No other complications or specific side effects related to the procedure were observed. Bilirubin levels were lower at 1 (2.19 ± 0.9) and 4 mo (2.10 ± 1.0) after cell transplantation that baseline levels (2.78 ± 1.2). Albumin levels 4 mo after BMC infusion (3.73 ± 0.5) were higher than baseline levels (3.47 ± 0.5). International normalized ratio (INR) decreased from 1.48 (SD = 0.23) to 1.43 (SD = 0.23) one month after cell transplantation. Conclusion: BMC infusion into hepatic artery of patients with advanced chronic liver disease is safe and feasible. In addition, a decrease in mean serum bilirubin and INR levels and an increase in albumin levels are observed. Our data warrant further studies in order to evaluate the effect of BMC transplantation in patients with advanced chronic liver disease. © 2007 The WJG Press. All rights reserved.
Description: p. 1067-1073
URI: http://repositorio.ufba.br/ri/handle/ri/15991
ISSN: 1007-9327
Appears in Collections:Artigos Publicados em Periódicos (Medicina)

Files in This Item:

File Description SizeFormat
Andre Lyra.pdf417.08 kBAdobe PDFView/Open
View Statistics

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

    Universidade Federal da Bahia

Contate-nos. Saiba mais sobre o RI/UFBA